放疗联合免疫治疗在局部晚期非小细胞肺癌中的疗效及安全性分析  

Analysis of the Efficacy and Safety of Radiotherapy Combined with Immunotherapy in Locally Advanced Non-small Cell Lung Cancer

作　　者：郑保珍 汪雅芬 董智慧 程庆伟 张倩倩 ZHENG Baozhen;WANG Yafen;DONG Zhihui;CHENG Qingwei;ZHANG Qianqian(Department of Oncology,Sixth Division Hospital of Xinjiang Production and Construction Corps,Wujiaqu 831300,Xinjiang Uygur Autonomous Region,China)

机构地区：[1]新疆生产建设兵团第六师医院肿瘤科,新疆维吾尔自治区五家渠831300

出　　处：《系统医学》2024年第16期143-146,158,共5页Systems Medicine

摘　　要：目的 分析晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)放疗联合免疫治疗的客观缓解率及安全性。方法 回顾性选取2022年11月—2023年11月新疆生产建设兵团第六师医院肿瘤科收治的不可手术的66例局部晚期NSCLC患者的临床资料,根据治疗方案不同进行分组,33例局部晚期NSCLC放疗联合免疫治疗患者作为观察组,33例放疗患者作为对照组。比较两组患者的客观缓解率及安全性等情况。结果 观察组客观缓解率为48.48%(16/33),高于对照组21.21%(7/33),差异有统计学意义(χ^(2)=5.406,P<0.05);两组不良反应发生率对比,差异无统计学意义(P>0.05);治疗前两组血清肿瘤标志物、生存质量评分、生活质量评分、免疫功能指标水平对比,差异无统计学意义(P均>0.05),治疗后,上述指标均较治疗前改善,且观察组优于对照组,差异有统计学意义(P均<0.05)。结论 放疗联合免疫治疗晚期NSCLC兼具有效性及安全性,可降低血清肿瘤因子表达水平,提高患者免疫功能,提高患者的生存与生活质量。Objective To analyze the objective response rate and safety of radiotherapy combined with immunotherapy for advanced Non-small cell lung cancer (NSCLC).Methods The clinical date of sixty-six inoperable patients with locally advanced NSCLC admitted to the Oncology Department of the Sixth Division Hospital of Xinjiang Production and Construction Corps from November 2022 to November 2023 were retrospectively selected.According to different treatment regiments,thirty-three patients with local advanced NSCLC treated with radiotherapy combined with immunotherapy were selected as the observation group and thirty-three patients treated with radiotherapy were selected as the control group.Objective response rate and safety were compared between the two groups.Results The objective remission rate in the observation group was 48.48%(16/33),which was higher than 21.21%(7/33) in the control group,the difference was statistically significant (χ^(2)=5.406,P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups (P>0.05).Before treatment,serum tumor marker,quality of life score,quality of life score and immune function index level were compared between the two groups,and the difference was not statistically significant (P>0.05).After treatment,the above indexes were improved compared with those before treatment,and the observation group was superior to the control group,the differences were statistically significant(all P<0.05).Conclusion Radiotherapy combined with immunotherapy for advanced NSCLC is both effective and safe,and can reduce the expression level of serum tumor factors,improve the immune function of patients,and improve the survival and quality of life of patients.

关 键 词：免疫治疗 放疗 不可手术的局部晚期非小细胞肺癌 血清肿瘤标志物 免疫功能 

分 类 号：R73[医药卫生—肿瘤]